Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Voyager Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was €-96.66 Mil. Voyager Therapeutics's average total tangible assets for the quarter that ended in Mar. 2026 was €202.58 Mil. Therefore, Voyager Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -47.72%.
The historical rank and industry rank for Voyager Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
FRA:VT6'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -48.84 Med: -22.73 Max: 51.83
Current: -40.63
During the past 13 years, Voyager Therapeutics's highest Return-on-Tangible-Asset was 51.83%. The lowest was -48.84%. And the median was -22.73%.
FRA:VT6's Return-on-Tangible-Asset is ranked worse than 53.43% of 1413
companies
in the Biotechnology industry
Industry Median: -35.77
vs FRA:VT6: -40.63
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Voyager Therapeutics Return-on-Tangible-Asset Related Terms
Voyager Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VT6 vs KROS, CDXS, CAMP: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Voyager Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -47.72% mean?
Voyager Therapeutics (FRA:VT6) has a Return-on-Tangible-Asset of -47.72% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #755 out of 1413 companies in the Biotechnology industry, placing it in the top 53.4%.
Is Voyager Therapeutics' Return-on-Tangible-Asset too high?
Voyager Therapeutics' current Return-on-Tangible-Asset is -47.72%. Based on the distribution chart, Voyager Therapeutics ranks #755 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Voyager Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Return-on-Tangible-Asset compare to KROS and CDXS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #755 out of 1413 companies for Return-on-Tangible-Asset. This places Voyager Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Return-on-Tangible-Asset is -47.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.41, compared to a current price of €3.06 — trading 116.7% above its estimated fair value. The current Return-on-Tangible-Asset is -47.72%. Voyager Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Return-on-Tangible-Asset is -47.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €3.06 is trading 116.7% above its estimated GF Value™ of €1.41.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
Return-on-Tangible-Asset: -47.72%
GF Value™: €1.41 vs. price of €3.06 (116.7% above fair value)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
52GF Score
Get the complete analysis for FRA:VT6
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
